Surabhi Dangi-Garimella, PhD

A research team at the Barts Cancer Institute in London has identified a 3-protein molecular signature in pancreatic cancer patients.

The discovery could lead to targeted therapy in triple negative breast cancer patients.

A study published in the American Journal of Preventive Medicine shows that grip strength of young, healthy adults could prove useful in the diagnosis of diabetes and hypertension.

A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.

Urologists at Cancer Research UK have identified 5 distinct genomic signatures in prostate cancer that can have important implications on treatment decisions.

A report released by the California Association of Health Plans projects a huge cost expenditure even if a small proportion of the state's hep C patients are treated with the potentially curative medications.

New research studies show that anti-inflammatory agents can improve survival as well as quality of life in cancer patients.

Physicians at the Brigham and Women's Hospital have published results from a proof-of-concept study that used mass spectrometry in almost real-time to detect and delineate pituitary tumors from normal tissue.

The California Department of Public Health has announced participation in a pilot project with St. Joseph Health to better understand cancer trends in California.

At the ongoing annual ACS NSQIP Conference in Chicago, physicians from the Thomas Jefferson University Hospital in Philadelphia presented a risk score tool that can predict a person's dependence on mechanical ventilation post surgery.

The FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus genotype 3 infections.

While the study found differences in hazard ratio for age-specific survival, improved care and better treatment options might have resulted in increased survival, the authors deduce.

ASCO's Breast Cancer Guideline Advisory Group and Clinical Practice Guideline Committee have published an updated guideline in the Journal of Clinical Oncology on using breast cancer biomarkers to guide clinical decisions when treating advanced metastatic breast cancer.

Merck (MSD) has announced that its PD-1 inhibitor pembrolizumab (Keytruda) was approved by the European Commission for the treatment of advanced (unresectable or metastatic) melanoma in adults.

Researchers at UCLA have discovered that inhibiting SGLT2 in pancreatic and prostate adenocarcinomas can reduce cancer cell survival.

The Exchange Pulse Report published by Express Scripts predicts that compared with 2014, the year 2015 will see a greater number of younger enrollees signing up on healthcare exchanges, which could potentially drive down drug costs for specialty medications.

A report released by the healthcare research group Avalere Health claims that health insurance exchanges have a significantly narrow network compared with their commercial counterparts.

A study published in JAMA Oncology questions aggressive local treatment strategies in men with low-risk prostate cancer.

At the annual meeting of the American Society of Clinical Oncology in Chicago, physicians introduced some new lymphoma treatments as they described their personal experience with using them during the session, "Incorporating Novel Agents Into Lymphoma Therapy: Value in Everyday Practice."

Immuno-oncology continues to deliver results in oncology, as seen from results presented at the annual meeting of the American Society of Clinical Oncology. The combination of nivolumab and ipilimumab significantly improved survival in melanoma, while elotozumab showed encouraging results in relapsed refractory multiple myeloma.

A late-breaking abstract session early at the annual meeting of the American Society of Clinical Oncology presented datd for nivolumab in the treatment of hepatocellular carcinoma, non-squamous cell non-small cell lung cancer, and for tumors harboring mismatch repair deficiency.

During the session "Health Services Research and Quality of Care" at the annual meeting of the American Society of Clinical Oncology, oncologists discussed factors that influence clinical trial participation and the cost of cancer care.

Scientists at the University of Leeds have developed a device that avoids the constant finger pricks in hyperglycemic patients.

A very popular session on the "value" of cancer care during the annual meeting of the American Society of Clinical Oncology (ASCO) brought together a patient representative, an oncologist, an ASCO representative, and a payer.

At the annual meeting of the American Society of Clinical Oncology, Robin Zon, MD, discussed the growing administrative burdens in oncology practice with the movement towards value-based payment.

The FDA warning last week on the cardiovascular effects of non-aspirin nonsteroidal anti-inflammatory drugs has prompted healthcare experts to advise caution when using these drugs on a regular basis.

Priority has seen about a 40% reduction in acute inpatient hospitalizations, 50% reduction in emergency department (ED) visits, and a 30% drop in per-member-per month costs among 300 of its chronically ill enrollees.

A poster presented at the 2015 annual meeting of the American Society of Clinical Oncology shared encouraging phase 3 survival data from the RECOURSE trial, after evaluating specific geographic subgroups.

During the Oncology Stakeholder's Summit 2015 hosted by AJMC, healthcare experts discuss the value of introducing palliative and end-of-life care discussions early in oncology care.

The American Journal of Managed Care invited healthcare experts to discuss the challenges associated with managing and paying for newer and more expensive agents in oncology, during the Oncology Stakeholders Summit.